CURRICULUM VITAE

PERSONAL INFORMATION:

Name: Ehab Saadeldin Hassan Alanwar Taher
Work Address: Faculty of Dentistry, Zarqa University, Zarqa, Jordan
E-mail: etaher@zu.edu.jo & ehabtaher.anu@gmail.com
Tel: +962 780645765
LinkedIn Page: https://www.linkedin.com/in/ehab-taher-1b775521/
Google scholar page: https://scholar.google.com/citations?hl=en&user=qovfJ0MAAAAJ
ORCID ID: https://orcid.org/0000-0002-1091-2885
Scopus Author ID: 56811239900
Scopus page: https://www.scopus.com/authid/detail.uri?authorId=56811239900

EDUCATION:

PhD degree, September 2017, at the Australian National University (top 50 globally), (Specialty: Pharmaceutical Organic Chemistry).

Master degree, October 2009, at Cairo University (Specialty: Pharmaceutical Organic Chemistry).

Bachelor of Pharmaceutical Sciences, May 2003, Faculty of Pharmacy, Al-Azhar University (Assiut branch). *General grade: Very good with Honor degree.*

EXPERIENCE IN THE FIELD OF ACADEMIC QUALITY ASSURANCE:

- Coordinator for the 7th standard (Academic standards and educational programmes) in Pharm D program at Faculty of pharmacy, Al-Azhar University (Assiut branch).

March 2016- April 2018

- I was responsible for the following:
  1. Learning outcomes for each course according to the academic standards at The National Authority for Quality Assurance and Accreditation. (NARS 2017).
  2. Course specification for Pharmaceutical Organic Chemistry course according to the Academic Reference Standards 2017.
  3. Blueprint per course exam according to the Academic Reference Standards 2017.
  4. The percentage of improvement calculation for each course in proportion to the educational process.
  5. Modification of courses in accordance with the Academic Reference Standards 2017.
  6. Reports of the courses in accordance with the academic reference standards (NARS 2017).
- Certified from Quality Assurance & Training Center at Al-Azhar University the following:
  a. Curriculum Mapping and Course Description
  b. Self-Institution Assessment
  c. Student Evaluation
  d. Research Design Skills
  e. Effective Presentation Skills

PROFESSIONAL EXPERIENCE & POSITIONS HELD:

10/2024-present

Assistant Dean for Quality Affairs, Faculty of Dentistry, Zarqa University, Zarqa, Jordan

10/2023-09/2024

Associate Professor at Department of Basic and Clinical Medical Sciences, Faculty of Dentistry, Zarqa University, Zarqa, Jordan

- Head of the Development and Quality Committee
- Member of the Examinations Committee
- Member of the Administrative Committee
- Member of the Study Plan Committee
- Chairman of the Safety and Infection Control Committee
- Member of the International Relations and Cooperation Committee
- Member of the following up instructions and standards of the Higher Education Accreditation Commission Committee
- Member of the Student attendance and absence committee

10/2022-9/2023

Postdoctoral fellow at the Australian National University, Canberra, Australia.
The duties continue to be focused on the following:

- Developing synthetic methods of a range of biologically active anti-cancer and anti-inflammatory compounds, including various structurally complex molecules and related systems.
- Developing synthetic methods to chemically produce material capable of hydrogen activation, and testing of these compounds in the context of producing tracing molecules in the analytical techniques of Nuclear Magnetic Resonance Spectroscopy and Magnetic Resonance Imaging.

09/2020-07/2022 (Part time)

Assistant Professor at Faculty of Pharmacy, South Valley University, Qena city, Qena, Egypt.

09/2018-07/2020 (Part time)

Assistant Professor at Faculty of Pharmacy, Egyptian Russian University, Badr city,

Cairo, Egypt.

05/2018-10/2022 (Full time)

Assistant Professor at Faculty of Pharmacy, Al-Azhar University, (Assiut branch), Egypt.

My duties continue to be focused on the following:

a. **Teaching pharmacology courses that include the following:**
   - Introduction to medical and pharmaceutical terminologies, medical abbreviations, medical idioms, suffixes and prefixes, medical terms pertaining to major body systems.
   - The general principles of pharmacology I course which include pharmacokinetics, pharmacodynamics, receptor theory, drug interaction and principle of therapeutics. This course integrates principles of pharmacology with conceptual knowledge of physiology and pathophysiology to disease processes regarding the autonomic, neuromuscular and autacoids.
   - The basic knowledge of pharmacology II course which integrates principles of pharmacology with conceptual knowledge of physiology and pathophysiology disease processes regarding drugs acting on cardiovascular systems, central nervous system, gastro-intestinal tract, pulmonary systems and hematologic disorders. Antihyperlipidemic drugs are also included.
   - Provide the students with the knowledge of pharmacology III including principles of pharmacology with conceptual knowledge of physiology and pathophysiology disease processes regarding drugs acting on endocrine system. Chemotherapeutic drugs including antimicrobials, anticancer and immunosuppressant are within the scope of the course. Stem cell therapy is also included. The anti-inflammatory, analgesics as well as gout treatments are also included.
   - Basic and Clinical Toxicology course. This course provides basics and concepts of toxicology including the mechanism of toxicity, target organ and treatment of toxicity. Toxic groups including heavy metals, toxic gases, animal, plant and marine poisons, pesticides and radiation hazards are covered. Environmental, occupational, reproductive and genetic toxicology as well as drug abuse are included. Postmortem sampling for detection of poisons, methods of detection, interpretation of results and writing of a report are also covered.

b. **Teaching pharmaceutical organic chemistry courses that include the following:**
   - The basic knowledge in pharmaceutical organic chemistry I which will serve as fundamentals for other courses offered during subsequent semesters. This course involves Electronic structure of atom, alkanes [nomenclature, synthesis and reactions (free radical reactions)], and cycloakanes. Alkenes, alkadienes and alkynes. Alkyl halides (nomenclature, preparation and chemical reactions (SN1, SN2, E1, E2). Aromaticity and arenes (Kekule structure, Huckel rule, Electrophilic aromatic substitution and orientation). In addition to aryl halides and alcohols.

- Provide students with knowledge in pharmaceutical organic chemistry II including stereochemistry (Optical isomers, racemic modification, nomenclature of configurations). In addition to, some classes as carbohydrates, aldehydes and ketones.
- Pharmaceutical organic chemistry III. This course involves different classes of organic compounds: nitrogenous compounds, phenols, ethers & epoxides, carboxylic acids & acid derivatives, sulphonic acids, amino acids and peptides.
- Pharmaceutical organic chemistry IV. This course involves the study of polynuclear and heterocyclic chemistry. In addition, it provides an introduction about the use of different spectroscopic tools; including UV, infrared (IR), nuclear magnetic resonance (NMR) and mass spectrometry (MS) for the structural elucidation of organic compounds.

c. **Assessment:**

- Regular class quizzes; - Mid. Module exam; - Written exam (short essay & MCQ).

d. **Research:**

- Guide students in Student Research Projects.
- Supervise academic activities of a group of students.

12/2016-01/2018

Technical support officer at the mass spectroscopy unit, Research School of Chemistry, the Australian National University, Canberra, Australia.

Under routine supervision of the Senior Technical Officer, the duties are:

1- Participate in and assist with supporting research facilities within the RSC as a member of the RSC Technical Services Team.
2- Assist in general lab duties, such as waste disposal, washing up and preparation of media and solutions commonly used in the lab;
3- Experimental design, and operation of standard laboratory and technical equipment and conduct of research procedures; Assist in the coordination of regular chemical inventories;
4- Assist in maintaining laboratories, equipment and communal areas, in a safe and efficient order; Assist with administrative duties associated with the RSC research equipment;
5- Comply with all ANU policies and procedures, and in particular those relating to work health and safety and equal opportunity;
6- Undertake other duties as consistent with the classification level of the position.

10/2009- 05/2013

Assistant lecturer at Faculty of Pharmacy, Al-Azhar University, (Assiut branch), Assiut, Egypt.

08/2003- 10/2009

Academic Tutor at Faculty of Pharmacy, Al-Azhar University, (Assiut branch), Assiut, Egypt (since August 2004).

I was responsible for:

1. Demonstrating and managing laboratories of the following courses:

a. Equipment and glassware safety for identifying equipment and glassware in the laboratory as well as safe handling procedure.
b. Crystallization and chromatographic techniques for organic compounds separation and purification and determination of melting point.
c. Limiting reagents in reactions and yields of reactions to understand how to predict how much product is produced by a reaction.

2. Teaching these courses required extensive professional knowledge in:

a. Introduction to first aid, basic life support and medical emergency of different situations including bleeding, shock, poisoning, bone fractures, soft tissue injuries, rescue and transportation. It includes: introduction to first aid ABCs, medical emergencies, effect of temperature, transportation of an injured casualty & first aid kit, respiratory emergencies, fractures and dislocations, bleeding and surgical emergencies, burns and scalds, animal bites or stings and poisoning.
b. Introduction to drug interaction. This course provides the knowledge and skills enabling them to develop professional competencies in the recognition and discussion of the pharmacological aspects of drug-drug, drug-chemical, drug-herb or drug-food interactions and their clinical significance as well as the application of that knowledge to minimize the risk and outcome of interactions. It covers different types of drug interaction including pharmaceutical interactions, pharmacokinetic interactions, pharmacodynamic interactions, herbal & food drug interactions, alcohol and smoking drug interactions, CNS drug interactions, interactions of cardiovascular acting drugs, interactions of anticoagulants, interactions of anti-infectives, interactions of antihistaminic & immune-based therapies, interactions of hormones, and drug-disease interactions.
c. Introduction to organic chemistry, modern atomic theory, electron transfer reactions, chemical bonding, ionic and covalent bonds, Lewis structures electronegativity and bond dipoles.
d. Atomic structure and periodicity, chemical bonding, nomenclature, acids and bases, oxidation and reduction, equation writing and simple organic compounds.

3. Guiding and supporting the students in naming the binary ionic compounds and binary compounds to be able to name binary compounds and compounds that contain polyatomic ion to be able to write formulas from names and vice versa.

4. Monitoring and supporting the students for identification and characterization of the newly synthesized biologically active compounds using different spectroscopic methods e.g. infrared (IR), Mass spectroscopy and Nuclear Magnetic resonance (^{1}H & ^{13}C NMR, COSY and NOESY).

5. Identification and characterization of the newly synthesized compounds using different spectroscopic methods infrared (IR), Mass spectroscopy, Nuclear magnetic resonance (^{1}H NMR & ^{13}C NMR), elemental and x-ray analyses.

ACHIEVEMENT & AWARDS:

- Postdoctoral fellowship from the Australian National University *(Australia, **2022**)*.
- Postgraduate PhD scholarship from the Australian National University (*Australia, **2013***).
- Islamic development bank merit PhD scholarship programme (*Saudi Arabia, **2011***).

PROFESSIONAL MEMBERSHIP:

- Peer reviewer in the journal Drug Design, Development and Therapy (Impact Factor: 3.208).
- Peer reviewer in the journal Bioorganic Chemistry (Impact Factor: 5.275).
- Peer reviewer in Journal of Medicinal Chemistry (Impact Factor: 7.446).
- Member of Egyptian syndicate of pharmacists.
- Member of Quality Assurance and Accreditation Center at Faculty of pharmacy,Al-Azhar University (Assiut branch).

SKILLS

- The principles of pharmacotherapeutics & management of the common disease states (e.g. cardiovascular diseases, gastrointestinal diseases, respiratory diseases, endocrine diseases, obstetrics and gynecology, rheumatic diseases, renal diseases, CNS diseases).
- The safe and effective handling of scientific glassware and other equipment associated with the conduct of research in organic chemistry;
- The ability to conduct the chromatographic separation and purification of biologically active compounds and the recrystallization of those that are obtained as solids;
- A detailed working knowledge of atomic structure and periodicity, chemical bonding, acids and bases, oxidation and reduction in organic chemistry, electron-transfer reactions, electronegativity.
- High-level skills concerned with the spectroscopic characterization and structural elucidation of organic compounds using the high-end techniques of one- and two-dimensional ^{1}H and ^{13}C NMR spectroscopy, infrared spectroscopy and mass spectrometry.
- Computer skills (ICDL, Microsoft Word, Excel, PowerPoint, Outlook and ChemDraw).
- Language: English (Very good); Deutsh: eins, zwei, drei (**400** hours).
- Basic statistics.

PUBLICATIONS LISTS:

46. Hyoid Bone-Based Gender Discrimination among Egyptians using The Multidetector Computed Tomography: Discriminant Function Analysis, Meta-analysis and Artificial Intelligence-Assisted Study" **Scientific Reports** January (2025) 15:2680, https://doi.org/10.1038/s41598-025-85518-w , (Citescore 2024: 6.9, Impact factor 2025: 4.379).

45. Prospective and challenges of locally applied repurposed pharmaceuticals for periodontal tissue regeneration, **Frontiers in Bioengineering and Biotechnology** 12 (2024), https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1400472/abstract , (Citescore 2023: 8.3, Impact factor 2023: 4.3).
44. Pyridazinone based derivatives as anticancer agents endowed with anti-microbial activity; Molecular design, synthesis, and biological investigation, **RSC Medicinal Chemistry** 2024, https://pubs.rsc.org/en/Content/ArticleLanding/2024/MD/D4MD00481G (Citescore 2023: 5.8, Impact factor 2023: 4.1)
43. The arsenic bioremediation using genetically engineered microbial strains on aquatic environments: An updated overview, **Heliyon** 10 (2024) e36314, (http://creativecommons.org/licenses/by/4.0/), (Citescore 2023: 4.0, Impact factor 2023: 3.4)
42. Pyroptotic inducers: Chemical classification, Mechanisms, and SAR analysis, **Molecular Diversity Journal** (Citescore 2022: 3.8, Impact factor 2023: 3.8).

41. Effect of autologous platelet-rich plasma on the fertility and quality of cryopreserved buffalo bull semen: a comparative study using OptiXcell® and tris egg yolk extenders, **BMC Veterinary Research** (2024) 20:250, https://doi.org/10.1186/s12917-024-04022-x (Citescore 2023: 4.8, Impact factor 2023: 2.3)
40. Empagliflozin impact on experimentally induced acetaminophen toxicity: Imprint of mitochondrial dynamics, biogenesis, and cGAS/STING signal in amending liver insult, **FASEB Journal** https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202400254RRR (Citescore 2022: 9.8, Impact factor 2022: 4.1)
39. Suppression of NLPR3 inflammasome orchestrates the protective efficacy of trion against isoprenaline – induced mycordial injury, **Frontiers in Pharmacology,** 2024 doi: 10.3389/fphar.2024.1412245 (Citescore 2022: 7.8, Impact factor 2022: 4.4)
38. Challenges of therapeutic applications and regenerative capacities of urine based stem cells in oral, and maxillofacial reconstruction **Biomedicine & Pharmacotherapy** 177,2024, 117005 https://doi.org/10.1016/j.biopha.2024.117005 (Citescore 2022: 11.9, Impact factor 2022: 6.9)
37. Alchemilla vulgaris modulates isopretrenol-induced cardiotoxicity: interplay of oxidative stress, inflammation, autophagy and apoptosis. **Frontiers in Pharmacology,** 2024 doi: 10.3389/fphar.2024.1412245 (Citescore 2022: 7.8, Impact factor 2022: 4.4)
36. Production and improving the quality of Domiati cheese and increasing its shelf life by using milk exposure magnetic fields **International Dairy Journal** 2024, 106033 In Press, https://doi.org/10.1016/j.idairyj.2024.106033 (Citescore 2022: 6.5, Impact factor 2022: 3.1)
35. "Harnessing the Power of Bee Venom for Therapeutic and Regenerative Medical Applications: An Updated Review", **Frontiers in Pharmacology** 15, 2024 doi:10.3389/fphar.2024.1412245 (Citescore 2022: 7.8, Impact factor 2022: 4.4)
34. Exploring the NRF2/HO-1 and NF-κB Pathways: Spirulina Nanoparticles as a Novel Approach to Combat Diabetic Nephropathy **ACS Omega** (2024) https://doi.org/10.1021/acsomega.4c02285 (Citescore 2022: 5.9, Impact factor 2022: 4.1)
33. Bioactive injectable mucoadhesive thermosensitive natural polymeric hydrogels for oral bone and periodontal regeneration **Frontiers in Bioengineering and Biotechnology (**2024) DOI 10.3389/fbioe.2024.1384326 (Citescore 2022: 6.7, Impact factor 2022: 5.7)
32. Discovery of novel octahydroquinazoline scaffolds endowed with dual inhibition of tubulin polymerization/Eg5 against HCC: Apoptotic and radio-chemotherapeutic studies **Bioorganic Chemistry** *2024*, 145, 107244. https://doi.org/10.1016/j.bioorg.2024.107449 (Citescore 2022: 9.5, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.1)
31. Prospectives and challenges of nano-tailored biomaterials-assisted biological molecules delivery for tissue engineering purposes **Life Sciences** 349 (2024) 122671 https://doi.org/10.1016/j.lfs.2024.122671 (Citescore 2023: 10.8, Impact factor 2024: 6.1)
30. The potential biological activities of *Aspergillus luchuensis*-aided green synthesis of silver nanoparticles **Frontiers in Microbiology** *2024,* 15, 1381302*,* https://doi.org/10.3389/ fmicb.2024.138 1302 (Citescore 2023: 7.8, Impact factor 2024: 5.2)
29. Protective effect of Petroselinum crispum methanolic extract against acrylamide-induced reproductive toxicity in male rats through NF-κB, kinesin, steroidogenesis pathways. **ReproductiveToxicology** *2024*, 126, 108586 https://doi.org/10.1016/j.reprotox.2024.108586 (Citescore 2022: 5.9, Impact factor 2022: 3.3)
28. Evaluating estrus synchronization and early pregnancy detection in Ossimi sheep: The influence of fluorogestone acetate treatment duration and dosage. **Veterinary and Animal Science** *2024*, 24, 100351 https://doi.org/10.1016/j.vas.2024.100351 (Citescore 2022: 3.7, Impact factor 2022: 1.5)
27. Tailored Tetrasubstituted Imidazole Carrying the Benzenesulfonamide Fragments as Selective Human Carbonic Anhydrase IX/XII Inhibitors **ChemMedChem** *2024*, e202400004, https://doi.org/10.1002/cmdc.202400004
26. Tailored quinoline hybrids as promising COX-2/15-LOX dual inhibitors endowed with diverse safety profile: Design, synthesis, SAR, and histopathological study. **Bioorganic Chemistry** *2024*,

145, 107244. https://doi.org/10.1016/j.bioorg.2024.107244 (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)

25. Design and synthesis of uracil/thiouracil based quinoline scaffolds as topoisomerases I/II inhibitors for chemotherapy: A new hybrid navigator with DFT calculation. **Bioorganic Chemistry** *2023*, 136, 106560. https://doi.org/10.1016/j.bioorg.2023.106560 (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)
24. Anticancer Activities of Tetrasubstituted Imidazole-Pyrimidine-Sulfonamide Hybrids as Inhibitors of EGFR Mutants. **ChemMedChem** *2023*, e202200641. doi.org/10.1002/cmdc.202200641
23. Schiff bases as linker in the development of quinoline-sulfonamide hybrids as selective cancer-associated carbonic anhydrase isoforms IX/XII inhibitors: A new regioisomerism tactic. **Bioorganic Chemistry** *2023,* 131, 106309. https://doi.org/10.1016/j.bioorg.2022.106309 (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)
22. Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline–Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors. **Pharmaceuticals *2022***, 15, 494. https://doi.org/10.3390/ph15050494 (Citescore 2021: 4, SJR 2021: 0.851, SNIP 2021: 1.223, Impact factor 2021: 5.215)
21. New pyrimidine/thiazole hybrids endowed with analgesic, anti-inflammatory, and lower cardiotoxic activities: Design,synthesis, and COX-2/sEH dual inhibition. **Arch. Pharm. *2022***, e2200024. https://doi.org/10.1002/ardp.202200024 (Citescore 2021: 2.2, SJR 2021: 0.536, SNIP 2021: , 0.68, Impact factor 2021: 4.613)
20. Synthesis, Antimicrobial, Anti-Virulence and Anticancer Evaluation of New 5(4H)- Oxazolone-Based Sulfonamides**. Molecules *2022*, 27, 671.** https://doi.org/10.3390/ molecules27030671 (Citescore 2021: 3.28, SJR 2021: 0.757, SNIP 2021: 1.166, Impact factor 2021: 4.927)
19. Novel Benzyloxyphenyl Pyrimidine-5-Carbonitrile Derivatives as Potential Apoptotic Antiproliferative Agents. Anti-Cancer Agents in Medicinal Chemistry *2021*, **DOI**: 10.2174/1871520621666210612043812 (Citescore 2021: 2.0, SJR 2021: 0.528, SNIP 2021: 0.675, Impact factor 2021: 2.866)
18. Novel Levothyroxine HIV-TAT Nanoconjugates Suppressing HeLa Cell Lines Growth in Management of Cervical Cancer. **International Journal of Pharmacology *2021*,** 17 (5) 300-307. (Impact factor 2021: 0.751)
17. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Tri-Aryl Imidazole-Benzene Sulfonamide Hybrids as Promising Selective Carbonic Anhydrase IX and XII Inhibitors. **Molecules *2021*, 26, 4718.** https://doi.org/10.3390/molecules26164718 (Citescore 2021: 3.28, SJR 2021: 0.757, SNIP 2021: 1.166, Impact factor 2021: 4.927)
16. Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. **Journal of enzyme inhibition and medicinal chemistry**, **2021**, 36, (1), 802–818. (Citescore 2022: 8.4, SJR 2022: 0.916, SNIP 2022: 1.517, Impact factor 2022: 5.756)
15. Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile. **Bioorganic Chemistry, *2021***, 111, 104890. (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)
14. Design, synthesis, biological evaluation, and computational studies of novel thiazolo-pyrazole hybrids as promising selective COX-2 inhibitors: Implementation of apoptotic genes expression for ulcerogenic liability assessment. **Bioorganic Chemistry, *2021***, 111, 104883. (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)
13. Potent combretastatin A-4 analogues containing quinoline: Design, Synthesis, antiproliferative, and anti-tubulin activity. ***Pharmaceuticals,* 2020**, 13, 393. (Citescore 2021: 4, SJR 2021: 0.851, SNIP 2021: 1.223, Impact factor 2021: 5.215)

12. Design and synthesis of novel pyrazolo [3, 4-d] pyrimidin-4-one bearing quinolone scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. ***Bioorganic Chemistry*, 2020**, *105*, 104352. (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)
11. In *Vitro* Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors. ***Molecules*, 2020**, 25 (14), 3125. (Citescore 2021: 3.28, SJR 2021: 0.757, SNIP 2021: 1.166, Impact factor 2021: 4.927)
10. Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors. ***Bioorganic Chemistry*, 2020**, *99*, 103782. (Citescore 2022: 5.4, SJR 2022: 0.728, SNIP 2022: 1.298, Impact factor 2022: 5.307)
9. Novel benzenesulfonamide and 1,2-benzisothiazol-3(2H)-one-1,1-dioxide derivatives as potential selective COX-2 inhibitors***. European Journal of Medicinal Chemistry,* 2019**, *171,* 372-382. (Citescore 2022: 9.8, SJR 2022: 1.177, SNIP 2022: 1.606, Impact factor 2022: 7.088)
8. Ameliorative and protective effects of ginger and its main constituents against natural, chemical and radiation-induced toxicities: A comprehensive review. ***Food and Chemical Toxicology*, 2019**, *123,* 72–97. (Citescore 2022: 10.2, SJR 2022: 1.61, SNIP 2022: 1.209, Impact factor 2022: 6.935)
7. The Exploitation of Enzymatically-Derived *cis*-1,2-Dihydrocatechols and Related Compounds in the Synthesis of Biologically Active Natural Products. ***Chemical Record,* 2018,** *18,* 239–264. (Citescore 2022: 9.8, SJR 2022: 1.177, SNIP 2022: 1.606, Impact factor 2022: 7.088)
6. The Synthesis of Certain Derivatives and Analogues of (−)- and (+)-Galanthamine and an Assessment of their Capacities to Inhibit Acetylcholine Esterase. ***Journal of Organic Chemistry* 2017,** *82, (15)* 7869-7886. (Citescore 2022: 7.5, SJR 2022: 1.2, SNIP 2022: 0.905, Impact factor 2022: 4.198)
5. The Synthesis of Certain Phomentrioloxin A Analogues and Their Evaluation as Herbicidal Agents. ***Journal of Organic Chemistry* 2017,** *82*, 211-233. (Citescore 2022: 7.5, SJR 2022: 1.2, SNIP 2022: 0.905, Impact factor 2022: 4.198)
4. Chemoenzymatic Pathways for the Synthesis of Biologically Active Natural Products. ***The Journal and Proceedings of the Royal Society of NSW* 2016,** *149,* 34-50. (Citescore 2022: 6.5, SJR 2022: 0.976, SNIP 2022: 1.593, Impact factor 2022: 4.803)
3. Chemoenzymatic Synthesis of (+) Asperpentyn and the Enantiomer of the Structure Assigned to Aspergillusol A. ***Journal of Natural Products* 2015,** *78*, 1963-1968. (Citescore 2022: 0.4, SJR 2022: 0.131, SNIP 2022: 0.096)
2. Synthesis of New Nonclassical Acridines, Quinolines and Quinazolines Derived from Dimedone for Biological Evaluation. ***Archive der Pharmazie Chemie* 2010,** *9*, 519–527. (Citescore 2021: 2.2, SJR 2021: 0.536, SNIP 2021: , 0.68, Impact factor 2021: 4.613)
1. New octahydroquinazoline derivatives: Synthesis and hypotensive activity. ***European Journal of Medicinal Chem*istry 2010,** *45*, 5390-5396. (Citescore 2022: 9.8, SJR 2022: 1.177, SNIP 2022: 1.606, Impact factor 2022: 7.088)

ii) Patents:

1. 4-((2-(2-(2-(4-methoxyphenyl)-4, 5-diphenyl-1H-imidazol-1-yl) acetyl) hydrazono) methyl) benzoic acid as an anti-cancer compound
   Publication date: 2024/3/26, Patent office: US, Patent number: 11939299, Application number: 18512463
2. 4-((2-(2-(2-(4-hydroxyphenyl)-4, 5-diphenyl-1H-imidazol-1-yl) acetyl) hydrazono) methyl) benzoic acid as an anticancer compound
   Publication date: 2024/3/19, Patent office: US, Patent number: 11932608, Application number: 18518285

PRESENTATIONS:

4. A Blurring of the Distinction between Disorder and Allo-twinning *Poster presentation at The Annual Meeting of the American Crystallographic Association, July 25-29th, **2015**, Philadelphia, Pennsylvania, USA.*

3. The Chemoenzymatic Synthesis of Biologically Active Analogues of (−)-Phomentrioloxin *Poster presentation at The 3rd International Conference on Chemical, Agricultural and Medical Sciences (CAMS-2015), December 10-11st, **2015**, Singapore.*

2. The Chemoenzymatic Synthesis of Biologically Active Analogues of (−)-Phomentrioloxin *Poster presentation at The Royal Australian Chemical Institute Organic One-Day Symposium, December 3rd, **2014**, Canberra, Australia.*

1. New octahydroquinazoline derivatives: Synthesis and hypotensive activity *Poster presentation at Al-Azhar 5th International Conference for Pharmaceutical and Biological Sciences July 15th, **2008**, Cairo, Egypt.*

ENGLISH PROFICIENCY:

***Communication Skill**:* I have been working in Australia since 2013. During this time, I had to communicate with my co-workers, supervisors, technical staff, external members and consultants. Moreover, during my academic career, I had to attend weekly meeting to present the progress in the work and the short-term future plan of the projects I had involved in. My Bachelor, Master and Ph.D were solely taught and examined in English.

Writing Skill: I wrote Master and Ph.D. theses.

REFERENCES:

1) **Professor Martin G. Banwell**
The Australian National University, Canberra, Australian Capital Territory 2601, Australia.
Tel: +61 2 61258202 E-mail: Martin.Banwell@anu.edu.au

2) **Professor Gamal El-Din A. Abuo-Rahma**
Faculty of Pharmacy, Minia University, Minia, Egypt.
Tel: +201003069431 E-mail: gamal.aborahama@mu.edu.eg

3) **Professor Hatem A. Abdel-Aziz**
National Research Centre (NRC), Dokki, 12622, Cairo, Egypt. Pharmaceutical Research Department, Centre of Excellence for Advanced Sciences, NRC, Cairo, Egypt.
Tel: +02 01009511215 E-mail: hatem_741@yahoo.com

4) **Professor Osama I. El-Sabbagh**
Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt
Tel: +201009610300 /+966595607625 E-mail: osamaelsabbagh@yahoo.com

5) **Dr. Philip Norcott**
The Australian National University, Canberra, ACT 2601, Australia; Tel: +61261258202
E-mail: philip.norcott@anu.edu.au